Published in Ann Transplant on January 01, 1997
Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation (2000) 0.95
Relative contribution of direct and indirect allorecognition in developing tolerance after liver transplantation. Liver Transpl (2008) 0.78
Pathology of Chronic Rejection: An Overview of Common Findings and Observations About Pathogenic Mechanisms and Possible Prevention. Graft (Georget Tex) (1998) 0.76
Genetic barriers in transplantation medicine. World J Transplant (2016) 0.75
Intestinal transplantation in children: current status. Pediatr Surg Int (2016) 0.75
The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 27.07
The dendritic cell system and its role in immunogenicity. Annu Rev Immunol (1991) 23.09
Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 14.94
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE. Surg Gynecol Obstet (1963) 8.04
Experiences with renal homotransplantation in the human: report of nine cases. J Clin Invest (1955) 6.64
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet (1994) 3.72
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Cell biology of atherosclerosis. Annu Rev Physiol (1995) 3.60
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
Migration patterns of dendritic cells in the mouse. Homing to T cell-dependent areas of spleen, and binding within marginal zone. J Exp Med (1988) 2.98
Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95
Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA (1989) 2.87
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
OBLITERATIVE VASCULAR CHANGES IN FOUR HUMAN KIDNEY HOMOTRANSPLANTS. Br Med J (1963) 2.78
Soluble HLA antigens in the circulation of liver graft recipients. Transplantation (1989) 2.48
Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci U S A (1993) 2.31
Transplantation milestones. Viewed with one- and two-way paradigms of tolerance. JAMA (1995) 2.20
The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation (1995) 2.13
Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol (1988) 2.06
Presence of hematopoietic stem cells in the adult liver. Nat Med (1996) 2.00
Pathology of human intestinal transplantation. Gastroenterology (1996) 1.98
Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest (1994) 1.97
Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80
Induction of DR/IA antigens in human liver allografts. An immunocytochemical and clinicopathologic analysis of twenty failed grafts. Transplantation (1985) 1.75
Self-ignorance in the peripheral T-cell pool. Immunol Rev (1993) 1.73
HLA compatibility and liver transplant outcome. Improved patient survival by HLA and cross-matching. Transplantation (1994) 1.71
Multilineage hematopoietic reconstitution of supralethally irradiated rats by syngeneic whole organ transplantation. With oarticular reference to the liver. Transplantation (1996) 1.65
Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation (1988) 1.61
Early and persistent induction of monocyte chemoattractant protein 1 in rat cardiac allografts. Proc Natl Acad Sci U S A (1993) 1.61
Donor dendritic cells after liver and heart allotransplantation under short-term immunosuppression. Lancet (1992) 1.61
Weaning of immunosuppression in long-term liver transplant recipients. Transplantation (1995) 1.59
Peritransplant injury to the myocardium associated with the development of accelerated arteriosclerosis in heart transplant recipients. Am J Surg Pathol (1994) 1.58
Incidence and severity of transplant coronary artery disease early and up to 15 years after transplantation as detected by intravascular ultrasound. J Am Coll Cardiol (1995) 1.58
Endocardial infiltrates in the transplanted heart: clinical significance emerging from the analysis of 5026 endomyocardial biopsy specimens. J Heart Lung Transplant (1993) 1.52
Endocardial infiltrates in human heart transplants: a serial biopsy analysis comparing four immunosuppression protocols. Hum Pathol (1990) 1.50
Coronary arterial pathology in the transplanted human heart. Int J Cardiol (1989) 1.49
Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation (1992) 1.45
Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol (1994) 1.45
The immunology of experimental liver transplantation in the rat. Immunology (1985) 1.45
Arterial endothelialitis in chronic renal allograft rejection: a histopathological and immunocytochemical study. Nephrol Dial Transplant (1994) 1.42
Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol (1997) 1.41
Arterial lesions associated with medial disorganization and fibrosis in endomyocardial biopsies from human cardiac allografts. Histopathology (1995) 1.41
Peripheral deletion of autoreactive CD8+ T cells in transgenic mice expressing H-2Kb in the liver. Eur J Immunol (1995) 1.40
Microchimerism: a stable state of low-ratio proliferation of allogeneic bone marrow. Transplant Proc (1977) 1.39
Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J (1993) 1.38
Sequential cytokine dynamics in chronic rejection of rat renal allografts: roles for cytokines RANTES and MCP-1. Proc Natl Acad Sci U S A (1995) 1.34
The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Transplant (1989) 1.34
Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation (1995) 1.32
Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Ann N Y Acad Sci (1995) 1.31
A histometric analysis of chronically rejected human liver allografts: insights into the mechanisms of bile duct loss: direct immunologic and ischemic factors. Hepatology (1989) 1.30
Development of a mouse aortic transplant model of chronic rejection. Microsurgery (1995) 1.28
Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis. Am J Pathol (1990) 1.28
Experimental graft arteriosclerosis. I. The Lewis-to-F-344 allograft model. Transplantation (1992) 1.26
The impact of HLA mismatches on the survival of first cadaveric kidney transplants. N Engl J Med (1994) 1.26
Why are lung allografts more vigorously rejected than hearts? J Heart Transplant (1987) 1.26
Upregulation of cytokines associated with macrophage activation in the Lewis-to-F344 rat transplantation model of chronic cardiac rejection. Transplantation (1995) 1.25
Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation (1996) 1.25
Origin of lymph node-derived lymphocytes in human hepatic allografts. Clin Transpl (1989) 1.24
Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts. Transplantation (1993) 1.24
Clinical small bowel or small bowel plus liver transplantation under FK 506. Transplant Proc (1991) 1.24
Cloning and characterization of allograft inflammatory factor-1: a novel macrophage factor identified in rat cardiac allografts with chronic rejection. J Clin Invest (1995) 1.23
Coronary atherosclerosis in transplanted mouse hearts. I. Time course and immunogenetic and immunopathological considerations. Am J Pathol (1994) 1.22
Histopathology of early and late human hepatic allograft rejection: evidence of progressive destruction of interlobular bile ducts. Hepatology (1985) 1.21
Ductular damage in liver transplant rejection: its similarity to that of primary biliary cirrhosis and graft-versus-host disease. Pathol Annu (1981) 1.20
Human atherosclerosis. IV. Immunocytochemical analysis of cell activation and proliferation in lesions of young adults. Am J Pathol (1993) 1.20
The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology (1987) 1.19
Chronic allograft rejection. Immunol Rev (1993) 1.18
The effect of race and ethnicity on kidney allograft outcome. Clin Transpl (1995) 1.18
Immune status of recipients following bone marrow-augmented solid organ transplantation. Transplantation (1995) 1.18
Peripheral blood chimerism in renal allograft recipients transfused with donor bone marrow. Transplantation (1994) 1.16
Rous-Whipple Award Lecture. Atherosclerosis: a defense mechanism gone awry. Am J Pathol (1993) 1.15
Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation (1991) 1.13
Sex mismatch as a risk factor for chronic rejection of liver allografts. Lancet (1995) 1.13
Chronic cardiac rejection: identification of five upregulated genes in transplanted hearts by differential mRNA display. Proc Natl Acad Sci U S A (1994) 1.13
Morphology of solid organ allograft arteriopathy: identification of proliferating intimal cell populations. Transplant Proc (1989) 1.12
Coronary atherosclerosis in transplanted mouse hearts. III. Effects of recipient treatment with a monoclonal antibody to interferon-gamma. Transplantation (1994) 1.12
Cardiac transplantation in the rat. I. The effect of histocompatibility differences on graft arteriosclerosis. Transplantation (1989) 1.12
Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arteriosclerosis. Circulation (1995) 1.11
Chronic rejection after liver transplantation: a study of clinical, histopathological and immunological features. Hepatology (1991) 1.11
Induction of transforming growth factor-beta during cardiac allograft rejection. J Immunol (1993) 1.10
Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. Transplantation (1993) 1.08
Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol (1995) 1.08
Acute myocardial infarction in cardiac transplant recipients. Am J Cardiol (1989) 1.05
Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant (1995) 1.04
Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. Transplant Proc (1991) 1.02
Chronic graft rejection. Curr Opin Immunol (1994) 1.02
Pathology and etiology of chronic rejection of the heart. Clin Transplant (1994) 1.02
Intestinal transplantation in children under FK 506 immunosuppression. J Pediatr Surg (1993) 1.02
Functional impairment of enteric smooth muscle and nerves caused by chronic intestinal allograft rejection regresses after FK506 rescue. Transplantation (1995) 1.02
Transplant coronary artery disease: histopathologic correlations with angiographic morphology. J Am Coll Cardiol (1991) 1.02
Lung allograft rejection in the rat. II. Specific immunological properties of lung grafts. Transplantation (1985) 1.02
Human transplant coronary artery disease: pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab Invest (1996) 1.01
Transplantation tolerance correlates with high levels of T- and B-lymphocyte activity. Proc Natl Acad Sci U S A (1989) 1.01
Evolution of liver transplantation. Hepatology (1982) 19.54
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Bone marrow as a potential source of hepatic oval cells. Science (1999) 8.52
Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11
Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09
The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40
The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24
Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19
Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04
Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64
Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet (1979) 6.23
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Examination and characterization of distribution system biofilms. Appl Environ Microbiol (1987) 5.85
Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53
Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Occurrence of Giardia and Cryptosporidium spp. in surface water supplies. Appl Environ Microbiol (1991) 5.31
Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24
Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Inactivation of biofilm bacteria. Appl Environ Microbiol (1988) 4.29
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12
Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12
Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08
Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08
Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Extended preservation of human liver grafts with UW solution. JAMA (1989) 3.99
Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91
The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84
Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
Hepatic trisegmentectomy and other liver resections. Surg Gynecol Obstet (1975) 3.66
Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Hepatic Retransplantation. Transplant Proc (1985) 3.62
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49
IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38
The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38
Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Delayed biliary duct obstruction after orthotopic liver transplantation. Surgery (1972) 3.26
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Changes in blood coagulation. Arch Surg (1966) 3.22
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Renal transplantation in baboons under FK 506. Surgery (1989) 3.17
Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg (1985) 3.17
Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16
Liver transplantation before 1 year of age. J Pediatr (1987) 3.15
In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14